Matthew Biegler
Stock Analyst at Oppenheimer
(2.80)
# 2,716
Out of 4,429 analysts
425
Total ratings
37.6%
Success rate
1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Rated: Hold | n/a | $124.87 | - | 16 | Jun 15, 2026 | |
| CTMX CytomX Therapeutics | Rated: Hold | n/a | $3.04 | - | 12 | Jun 15, 2026 | |
| ARVN Arvinas | Rated: Hold | n/a | $7.74 | - | 17 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Rated: Hold | n/a | $34.23 | - | 20 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Hold | n/a | $8.93 | - | 23 | Jun 15, 2026 | |
| RLAY Relay Therapeutics | Rated: Hold | n/a | $17.28 | - | 18 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Rated: Hold | n/a | $10.00 | - | 23 | Jun 15, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 | $2.10 | +233.33% | 9 | May 14, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 | $30.14 | +65.89% | 23 | May 14, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Reiterated: Buy | $9 | $3.67 | +145.23% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $18.65 | +50.13% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.23 | +631.71% | 14 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $7.85 | +180.25% | 5 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.95 | - | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $4.44 | +575.68% | 8 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $865 | $612.50 | +41.22% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.77 | +297.88% | 23 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $17.50 | +157.14% | 2 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.58 | +406.33% | 13 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.15 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.14 | n/a | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $14.94 | n/a | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21.25 | $2.12 | n/a | 25 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11.34 → $4.25 | $0.415 | n/a | 12 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.65 | n/a | 15 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $0.2789 | n/a | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.7465 | n/a | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.79 | n/a | 6 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $50 | $1.37 | n/a | 15 | Feb 17, 2022 |
Gilead Sciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $124.87
Upside: -
CytomX Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $3.04
Upside: -
Arvinas
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $7.74
Upside: -
IDEAYA Biosciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $34.23
Upside: -
ORIC Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $8.93
Upside: -
Relay Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $17.28
Upside: -
Olema Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $10.00
Upside: -
Allogene Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $2.10
Upside: +233.33%
Tyra Biosciences
May 14, 2026
Reiterated: Buy
Price Target: $50
Current: $30.14
Upside: +65.89%
Zentalis Pharmaceuticals
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $3.67
Upside: +145.23%
May 13, 2026
Reiterated: Buy
Price Target: $28
Current: $18.65
Upside: +50.13%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.23
Upside: +631.71%
May 13, 2026
Reiterated: Buy
Price Target: $22
Current: $7.85
Upside: +180.25%
May 12, 2026
Rated: Hold
Price Target: n/a
Current: $9.95
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $30
Current: $4.44
Upside: +575.68%
Apr 30, 2026
Reiterated: Buy
Price Target: $865
Current: $612.50
Upside: +41.22%
Apr 28, 2026
Reiterated: Buy
Price Target: $15
Current: $3.77
Upside: +297.88%
Mar 27, 2026
Reiterated: Buy
Price Target: $45
Current: $17.50
Upside: +157.14%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $1.58
Upside: +406.33%
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.15
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: n/a
Current: $4.14
Upside: n/a
Dec 9, 2024
Maintained: Buy
Price Target: $160
Current: $14.94
Upside: n/a
Oct 31, 2023
Maintained: Buy
Price Target: $21.25
Current: $2.12
Upside: n/a
Aug 14, 2023
Maintained: Buy
Price Target: $11.34 → $4.25
Current: $0.415
Upside: n/a
Jul 31, 2023
Rated: Hold
Price Target: n/a
Current: $12.65
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $18
Current: $0.2789
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.7465
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.79
Upside: n/a
Feb 17, 2022
Maintained: Buy
Price Target: $8 → $50
Current: $1.37
Upside: n/a